肿瘤细胞治疗研究
ALL SOURCES
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
肿瘤学的治疗范式正在经历由抗体药物偶联物（ADC）和双特异性抗体（bsAb）驱动的深刻变革。
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.
72 名参与者的一个亚组接受了 CARTx 后疫苗反应的评估。
Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens.
将T淋巴细胞重定向至癌细胞是过去几年肿瘤学领域最有前景的治疗理念之一，并已促使过继性细胞治疗（ACT）和T细胞衔接双特异性（TEB）分子获得多项监管批准。
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target
基于特异性、疗效和靶抗原丢失，CARLY3 代表了一种针对非霍奇金淋巴瘤的潜在新型 CAR 治疗。
ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.
CD19 CAR-T 疗法在复发/难治性非霍奇金淋巴瘤（NHL）中已取得显著缓解。
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
在过去几年中，双靶点嵌合抗原受体（CAR）T细胞疗法已被用于血液系统恶性肿瘤的治疗，以减少治疗失败，特别是在抗原逃逸的情况下。
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
免疫细胞衔接器是工程化抗体，至少一个臂结合肿瘤相关抗原，至少另一个臂靶向免疫效应细胞上的激活受体：CD3用于招募T细胞，CD16a用于NK细胞。
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study.
这些数据支持在CAR-T细胞治疗前后考虑接种流感疫苗及其他相关病原体（如SARS-CoV-2）疫苗，无论是否存在低丙种球蛋白血症或B细胞发育不全。
Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.
抗CD38抗体目前构成了治疗AMR证据最强的药物类别。
Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.
B 细胞通过自身抗体产生、抗原提呈和细胞因子失调，以及致病性 B 细胞或浆细胞区室的持续存在，驱动 B 细胞恶性肿瘤和多种自身免疫性疾病。
MEMBER ACCOUNT
登录成功会直接打开下一页。
